Incyte (INCY) | Stock Overview & Key Data

Incyte Corporation | Healthcare

$61.16

0.58%

| Compare Stocks:

Incyte vs Vertex Incyte vs Regeneron Incyte vs Alnylam Incyte vs Royalty Pharma plc Incyte vs Insmed Incyte vs S&P 500 | Market

Incyte Performance Comparison

Loading chart data...

Incyte

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $59.15 High: $62.50

on May 14, 2025

52 Week Range

Low: $53.56 High: $83.95

on April 9, 2025

on November 8, 2024

All-Time High: $153.15 on March 13, 2017

Key Statistics

Market Cap i $11.8B

EPS i 0.20

P/E Ratio (TTM) i 304.25

Forward P/E i 9.91

P/B Ratio i 3.22

PEG Ratio i 9.91

Div. Yield i 0.00%

ROE i 0.47%

Beta i 0.680

Debt to Equity i 1.18

Financial Highlights

Profitability

Gross Margin i 93.05%

Operating Margin i 20.65%

Profit Margin i 0.48%

Returns and Earnings

Return on Assets (TTM) i 2.04%

Return on Equity (TTM) i 0.47%

EBITDA i $332.1M

Net Income (TTM) i $21.3M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Incyte INCY	11.78B Large-cap	2.67%	3.24%	-13.18%	-21.34%	-12.07%	7.08%	-18.35%	-38.47%
Vertex VRTX	112.83B Large-cap	-3.20%	-15.11%	-8.30%	-13.03%	3.73%	-5.40%	62.87%	47.80%
Regeneron REGN	62.15B Large-cap	1.87%	0.07%	-15.17%	-26.97%	-20.10%	-41.83%	-13.58%	0.25%
Alnylam ALNY	34.89B Large-cap	-3.25%	11.48%	4.33%	3.74%	14.53%	79.09%	102.28%	90.41%
Royalty Pharma plc RPRX	19.04B Large-cap	-1.37%	0.03%	-0.19%	26.27%	25.24%	18.41%	-18.29%	-34.10%
Insmed INSM	12.34B Large-cap	-3.91%	-7.63%	-17.27%	-7.93%	-6.20%	164.88%	224.00%	155.79%

Ownership & Short Interest

Insider Ownership i 2.22%

Institutional Ownership i 97.78%

Shares Short i 7M

Short Ratio i 2.89

Short % of Shares Outstanding i 5.44%

Average 10-Day Volume i 2M

Average 90-Day Volume i 2M

Incyte Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Incyte would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is INCY's 52-week high and low?

In the last 52 weeks, Incyte reached a high of $83.95 (on November 8, 2024) and a low of $53.56 (on April 9, 2025).

What is the market cap and P/E ratio for INCY?

Curious about Incyte's size and valuation? Its market capitalization stands at 11.78B. When it comes to valuation, the P/E ratio (trailing twelve months) is 304.25, and the forward P/E (looking ahead) is 9.91.

Does INCY pay dividends? If so, what's the yield?

As for dividends, Incyte isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Incyte's main competitors or similar companies to consider before investing?

When looking at Incyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	112.83B	Healthcare	Biotechnology	-5.40%	62.87%
Regeneron REGN	62.15B	Healthcare	Biotechnology	-41.83%	-13.58%
Alnylam ALNY	34.89B	Healthcare	Biotechnology	79.09%	102.28%
Royalty Pharma plc RPRX	19.04B	Healthcare	Biotechnology	18.41%	-18.29%
Insmed INSM	12.34B	Healthcare	Biotechnology	164.88%	224.00%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Incyte Corporation? (e.g., ROE, Debt/Equity)

To get a sense of Incyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 0.47%, the Debt to Equity ratio from the most recent quarter is 1.18, and its Gross Profit Margin stands at 93.05%.

What is the recent revenue and earnings growth for INCY?

Looking at Incyte's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 19.50%, and quarterly earnings saw a YoY growth of -6.70%.

How much of INCY stock is held by insiders and institutions?

Wondering who owns Incyte stock? Company insiders (like executives and directors) hold about 2.22% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.78%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.